Mend Secures Strategic Funding to Advance Life Sciences and Digital Health Mission
Mend, a life sciences and digital health company focused on integrating nutrapharma, food‑as‑medicine products and behavioral health interventions to accelerate recovery and improve patient outcomes, has continued to attract significant investor support as it scales its clinical, product and national expansion efforts. The company, headquartered in New York and led by CEO Eziah Syed, aims to bridge gaps in mainstream healthcare by combining evidence‑based nutritional products with AI‑powered digital coaching and clinical services designed to support perioperative recovery, chronic care, and lifestyle‑driven health challenges.
Mend announced a $15 million Series A funding round that underscores investor confidence in its integrated approach to healing, recovery and long‑term health optimization. The round was led by S2G Ventures, a multi‑stage investment firm dedicated to backing innovative, market‑based solutions that advance a healthier planet and strengthen the intersection of food, agriculture, health and wellness. S2G’s lead investment reflects its belief in Mend’s potential to narrow the divide between nutraceutical and pharmaceutical care through scientifically backed products and digital engagement tools that extend clinical outcomes beyond traditional settings.
Participating in the Series A financing were several prominent venture and strategic investors that bring a blend of capital, health‑sector expertise, and operational insight to Mend’s growth. Among these were iSelect Fund, a data‑driven venture fund that invests across early‑stage companies; Touchdown Ventures, which partners with corporations and startups to scale innovations in healthcare and technology; Colorcon Ventures, the corporate venture arm of Colorcon Inc. with a focus on pharmaceutical and nutraceutical markets; Keen Growth Capital, an early‑stage fund backing scalable technologies; GenHenn Capital, focused on high‑growth companies tied to impactful health outcomes; and Alumni Ventures, a multi‑stage venture firm with broad sector exposure. These investors collectively signal strong market interest in Mend’s integrated platform that blends physical, behavioral and nutritional health.
The funding will be directed toward several strategic priorities, including expanding Mend’s nationwide clinical and provider network, enhancing its research and development capabilities, and scaling its nutrapharma product lines that have demonstrated clinical efficacy in accelerating healing and reducing modifiable risk factors. These products are integrated with Mend’s Upgraid™ by Mend digital coaching platform—a human‑first, SMS‑based and AI‑enabled system that helps hospital systems extend recovery and wellness beyond hospital walls by supporting patients into healthier habits that last.
According to Mend’s leadership, the Series A funding will also support execution of existing provider contracts and the expansion of care delivery models that combine digital behavioral health coaching with evidence‑based nutritional interventions. This combination aims to reduce provider stress, enhance patient care and improve long‑term health outcomes while driving adoption among healthcare systems seeking integrated, scalable solutions. Early clients have already begun making Mend’s integrated care model part of their standard of care, demonstrating the practical impact of its offerings.
Mend’s nutrapharma products are described as clinically proven, science‑backed and recognized by medical professionals for their ability to accelerate repair, recovery and improve key risk factors contributing to chronic disease conditions. The company works collaboratively with hospitals, universities and leading health systems to develop evidence‑based programs and enhance patient outcomes, making it one of the first firms to meaningfully combine nutritional therapeutics with digital and behavioral health solutions at scale.
CEO Eziah Syed has emphasized that Mend’s mission goes beyond traditional wellness or supplement businesses; the company seeks to transform how recovery and health optimization are delivered, integrating direct‑to‑patient support with clinical care pathways and digital technologies. By doing so, Mend aims to address not only perioperative and chronic care challenges but also broader lifestyle‑preventable illness through proactive measures that empower individuals and support healthcare providers.
Mend’s investor base reflects a diverse set of strategic interests, from health‑focused venture firms to corporate backers with expertise in pharmaceuticals, nutraceuticals and digital health innovation. This broad support positions the company to navigate the complexities of healthcare integration and expand its impact across patient populations, providers and payors.
With a solid capital foundation and a strong mission‑driven vision, Mend is poised to continue its growth trajectory—advancing both its product portfolio and its role in evolving care delivery models that better meet the needs of patients and healthcare systems in an era defined by rising chronic disease burdens and the demand for more holistic, evidence‑based care solutions.
